Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
This article was originally published in PharmAsia News
You may also be interested in...
Will Teva's Deal With AstraZeneca Over Nexium Patents Erode Ranbaxy's Marketing Exclusivity In 2014?
MUMBAI - Teva's patent dispute settlement with AstraZeneca for a delayed launch of generic copies of the blockbuster heartburn drug brand Nexium (esomeprazole) led to enormous confusion and panic among Indian stock market investors regarding the status of Ranbaxy's 180-day sole marketing exclusivity for the drug starting May 2014
Will Teva's Deal With AstraZeneca Over Nexium Patents Erode Ranbaxy's Marketing Exclusivity In 2014?
MUMBAI - Teva's patent dispute settlement with AstraZeneca for a delayed launch of generic copies of the blockbuster heartburn drug brand Nexium (esomeprazole) led to enormous confusion and panic among Indian stock market investors regarding the status of Ranbaxy's 180-day sole marketing exclusivity for the drug starting May 2014
PharmAsia News’ Top 2008 Stories
With our first year of publishing PharmAsia News closing, we take this opportunity to look back at the top stories published in 2008. In case you missed them, here is your opportunity to check out the top stories covered this year in PharmAsia News, broken down by region